anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study presents the results of a randomized controlled trial utilizing a 2 x 2 factorial design, comparing the effects of repeated transcranial magnetic stimulation (rTMS) and action observation training (AOT) intervention methods on spasticity, balance function, and motor function in children with spastic cerebral palsy (SCP). The study aimed to investigate whether the combination of the two interventions produces greater improvement than either treatment alone or conventional treatment. Subject children in this study, in accordance with the random number table, were randomly divided into four groups: conventional group, rTMS group, AOT group, and combined intervention group. All the children in the four groups received conventional rehabilitation treatment, on the basis of which they were given different therapeutic programs of rehabilitation measures. The conventional group had no other treatment while the rTMS group received rTMS, the AOT group received AOT and the combined intervention group was given a combined intervention of rTMS and AOT. They were trained five days per week for 12 weeks. Changes in scores of spasticity, balance function, walking ability, and gross motor function were assessed at the onset of the training program and upon completion of 12 weeks of treatment. A total of 64 Children with SCP completed the study, and their results were analyzed. The total gross motor function efficiency of 87.50% in the experimental group was significantly higher than that of 25.00% in the conventional group, 62.50% in the rTMS group, and 68.75% in the AOT group. The preliminary results showed that combined intervention of rTMS and AOT could effectively improve the balance function and motor function of children, and the therapeutic effect of the combined intervention was better than that of conventional treatment, rTMS or AOT alone. Finally, clinical efficacy and optimal treatment parameters of the combined intervention were clarified to provide a clinical basis for therapists to conduct lower limb function rehabilitation for children with SCP.
PURPOSE:To provide an antioxidant having excellent oxidation inhibition properties and useful for food, cosmetic and medicine, which comprises a taste tea extract. CONSTITUTION:Leaves of a taste tea which is a coniferous tree of the genus Aspalathus, the family Linearis produced in South African Republic are dried and finely pulverized, if desired, followed by immersing in chloroform etc. so as to remove undesired pigment. Ethanol is added to the pulverized leaves, and the mixture is agitated at room temp. - 50 deg.C for about 1 week and filtered, thereby obtaining a filtrate of dark greenish brown. Then, the solvent of this filtrate is distilled off, and the remaining matter is dried under reduced pressure, thereby preparing an antioxidant comprised of a taste tea extract. This antioxidant may be added in an amt. of 0.001-5wt% to food, cosmetic, medicine or raw materials therefor.
Over the last decades, the survival of multiple myeloma (MM) patients has considerably improved. However, despite the availability of new treatments, most patients still relapse and become therapy-resistant at some point in the disease evolution. The mutation profile has an impact on MM patients' outcome, while typically evolving over time. Because of the patchy bone marrow (BM) infiltration pattern, the analysis of a single bone marrow sample can lead to an underestimation of the known genetic heterogeneity in MM. As a result, interest is shifting towards blood-derived liquid biopsies, which allow for a more comprehensive and non-invasive genetic interrogation without the discomfort of repeated BM aspirations. In this review, we compare the application potential for mutation profiling in MM of circulating-tumor-cell-derived DNA, cell-free DNA and extracellular-vesicle-derived DNA, while also addressing the challenges associated with their use.
Each participant will be in the study for about 1 month. The questionnaires consist of Chubon Quality of Life Rating, the Multi-dimensional Fatigue Inventory, Insomnia Severity Index, the Epworth Sleepiness, Pittsburgh Sleep Quality Index. Subjects will be screened with a medical questionnaire, vital signs, height, weight, oximetry to identify sleep apnea, a CBC and chemistry panel and the Insomnia severity Index. Weight, vital signs, adverse event questioning, dispensing and collection of test material will be done at each visit. During each treatment week subjects will wear an actigraph, keep a sleep diary and at the beginning and end of each treatment week subjects will have a polysomnography. At the end of each treatment period subjects will have a chemistry panel, a CBC, and a buffy coat will be archived.
Paclitaxel 135 mg/m\^2 intravenous (IV) over 1 hour; Gemcitabine 900 mg/m\^2 IV over 90 min; Doxorubicin 40 mg/m\^2 IV over 20 min; treatment may repeat every 2 weeks for up to nine courses. Injection of Pegfilgrastim on day 1.
Magnesium sulfate in water for injection is a sterile, nonpyrogenic, clear and colorless solution of magnesium sulfate heptahydrate, USP in water for injection, USP. May contain sulfuric acid and/or sodium hydroxide for pH adjustment. The pH is 4.5 (3.5 to 6.5). It is available in 4% concentration. See HOW SUPPLIED section for the content and characteristics of available dosage forms and sizes. 

Magnesium sulfate heptahydrate is chemically designated as MgSO4 • 7H2O and its molecular weight is 246.5 g/mol and having below structural formula:

Magnesium sulfate heptahydrate, USP is white or almost white crystalline powder or brilliant colorless crystals which is freely soluble in water, very soluble in boiling water, practically insoluble in ethanol (96%). 

Water for Injection, USP is chemically designated H2O.

The flexible plastic container is fabricated from a specially formulated non polyvinylchloride.
This is a single institute, single-arm, interventional trial to evaluate the efficacy and toxicity of concurrent chemoradiotherapy (CCRT) followed by Tegafur, Gimeracil and Oteracil Potassium Capsules consolidation chemotherapy in patients with locally advanced cervical cancer. The main inclusive criteria are as follows: histology confirmed cervical cancer; 18-70 years old; 2018 International Federation of Gynecology and Obstetrics (FIGO) stage IIB-IIIC2; ECOG score \<=1 point. The estimated enrollment is 200 patients. After enrollment, patients will receive CCRT, including external beam radiotherapy, intracavitary brachytherapy and concurrent chemotherapy. One month after the completion of CCRT, patients will receive 6 cycles of Tegafur, Gimeracil and Oteracil Potassium Capsules consolidation chemotherapy. The primary endpoint is progression free survival. And the secondary endpoints include overall survival, distant metastasis-free survival, local regional recurrence-free survival, acute toxicities, late toxicities, and treatment compliance.
PURPOSE:To further enhance the emulsifying capability of the title composition as compared with enzyme-treated lecithin and to appropriately apply the composition to food by mixing phospholipid such as enzyme-treated powdery lecithin and a monoglyceride to prepare the emulsifier composition. CONSTITUTION:The phospholipid such as enzyme-treated degummed oil cake, pasty lecithin, powdery lecithin, and refined high-purity lecithin and a monoglyceride are mixed to prepare the emulsifier composition. The phospholipid is commercially called lecithin, and classified into degummed oil cake, pasty lecithin obtained by dehydrating the oil cake and contg. a triglyceride, etc., in accordance with the purification degree. A monoglyceride contg. a saturated fatty acid is appropriately used as the monoglyceride. The content of the enzyme-treated phospholipid in the emulsifier is controlled to >=1wt.%, and the content of the monoglyceride is appropriately adjusted to the 1-10wt.% of the enzyme-treated phospholipid.
We report a very rare case of delayed necrosis of the reconstructed colon 6 months after esophagectomy.A 67-year-old male patient had undergone esophagectomy with gastric tube reconstruction for esophageal cancer in 2014. Subsequently, total gastrectomy and ileo-colon reconstruction via a retrosternal route was performed for gastric tube cancer in 2022. Six months later, he suffered acute chest pain and came to our hospital. Contrast-enhanced CT showed severe dilation of the reconstructed colon with poor enhancement of the wall opposite mesentery, without arterial obstruction. Endoscopy showed no ischemic changes in the esophago-ileum anastomosis; however, mucosal color change to black was observed in the reconstructed colon. We diagnosed ischemic colitis of the reconstructed colon and started conservative treatment; however, 18 days later, he developed a right pyothorax due to perforation of the reconstructed colon. We performed necrosed colectomy with right chest drainage and cervical esophageal fistula was made. Histopathological examination revealed mucosal detachment, thinning of the muscularis propria, and ghost-like appearance of crypt. If necrosis of the reconstructed colon is suspected in the late postoperative period, endoscopic findings of the colonic mucosa may be useful in determining surgical treatment, even in the absence of arterial blood flow obstruction.
Post treatment arm 1 for training set (IDH-wild type ATDGs, N=50; IDH-mutant ATDGs, N=50): The study aims to compare the genetic differences of ATDGs in terms of IDH mutation status. Samples of primary tumors are preferred but can be replaced with recurrent ones. Paired samples are both eligible for typing if the recurrent diseases of IDH-mutant tumors possess potential altered genes (such as up grading per histology features).
<P>PROBLEM TO BE SOLVED: To provide a remedy of cerebrovascular dementia, safely usable over a long period, and to provide a food and drink and an auxiliary food containing the remedy.  <P>SOLUTION: Histidine and/or a compound having the histidine at the N terminus exhibits activity for inhibiting neurocyte death by zinc, deeply concerning with the cerebrovascular dementia. The histidine has conventionally been utilized as a supplement, and is a compound of which the safety is highly evaluated. A product useful for the prevention or amelioration of the cerebrovascular dementia safely usable over a long period can be provided by the utilization of the histidine and/or the compound having the histidine at the N terminus. The histidine and/or the compound having the histidine at the N terminus can be either of a synthetic or a natural product. These are not necessarily required to be isolated, and the effects are exhibited only when an effective amount thereof is contained. Therefore, for example, a broth of Etrumeus teres can be used.  <P>COPYRIGHT: (C)2010,JPO&INPIT
Oral pouch 1g, single dose. One pouch administered over 30 minutes.
Hepatosplenic T-cell lymphoma (HSTCL) is an uncommon and highly aggressive subtype of peripheral T-cell lymphoma characterized by liver, spleen, and bone marrow involvement. Allogeneic hematopoietic stem cell transplantation (alloHSCT) is the only curative treatment for HSTCL, but it carries a significant risk of relapse. Cytomegalovirus (CMV) reactivation is a frequent complication after alloHSCT, particularly in patients undergoing lymphocyte-toxic therapies. A 27-year-old man diagnosed with HSTCL underwent an alloHSCT with active disease after six lines of therapy. A CMV reactivation was successfully treated with foscarnet. A sudden reappearance of symptomatic lymphocytosis (15,550/μL) by day +20, prior to engraftment, raised suspicion of disease progression. A comprehensive diagnostic work-up revealed an oligoclonal expansion of donor lymphocytes along with complete donor chimerism, leading to an alternative diagnosis of a CMV-driven T-cell expansion. This was confirmed by an in vitro assay testing T-cell specificity against CMV. The patient achieved both complete response and complete donor chimerism despite persisting lymphocytosis, but ultimately relapsed. This case highlights the importance of diagnostic tools in understanding disease progression and guiding treatment decisions.
FIELD: organic chemistry. SUBSTANCE: product: compound of the formula. Invention relates to the new derivatives of amides that are pyrido[3,4-b]indole-2-yl-acetamides of the formula (I)which are inhibitors of human leukocyte elastase. Invention involves also intermediate compounds that can be useful for synthesis of indicated amide derivatives, methods of synthesis of amide derivatives, pharmaceutical compositions containing indicated amide derivatives and methods of their use. Synthesized compounds can be used as a tool in pharmacological, diagnostic studies, for treatment of diseases in mammalian where elastase takes part. EFFECT: improved method of synthesis, enhanced inhibiting activity.
Oxidative stress-induced DNA damage and its repair systems are related to cancer etiology; however, the molecular basis triggering tumorigenesis is not well understood. Here, we aimed to explore the causal relationship between oxidative stress, somatic mutations in pre-tumor-initiated normal tissues, and tumor incidence in the small intestines of MUTYH-proficient and MUTYH-deficient mice. MUTYH is a base excision repair enzyme associated with human colorectal cancer. Mice were administered different concentrations of potassium bromate (KBrO3; an oxidizing agent)-containing water for 4 wk for mutagenesis studies or 16 wk for tumorigenesis studies. All Mutyh -/- mice treated with >0.1% KBrO3 developed multiple tumors, and the average tumor number increased dose dependently. Somatic mutation analysis of Mutyh -/-/rpsL transgenic mice revealed that G:C  > T:A transversion was the only mutation type correlated positively with KBrO3 dose and tumor incidence. These mutations preferentially occurred at 5'G in GG and GAA sequences in rpsL This characteristic mutation pattern was also observed in the genomic region of Mutyh -/- tumors using whole-exome sequencing. It closely corresponded to signature 18 and SBS36, typically caused by 8-oxo-guanine (8-oxoG). 8-oxoG-induced mutations were sequence context dependent, yielding a biased amino acid change leading to missense and stop-gain mutations. These mutations frequently occurred in critical amino acid codons of known cancer drivers, Apc or Ctnnb1, known for activating Wnt signal pathway. Our results indicate that oxidative stress contributes to increased tumor incidence by elevating the likelihood of gaining driver mutations by increasing 8-oxoG-mediated mutagenesis, particularly under MUTYH-deficient conditions.
In the first group, patients will receive intravenous, systemic, multimodal analgesia: paracetamol 1 gram and ketoprofen 100 mg every 8 hours for 24 hours. Analgesia will start immediately after surgery. If the pain persists, the patient will be given "rescue" analgesia: tramadol 50 mg intravenously up to a maximum dose of 400 mg / 24 h and other analgesics if needed.
The present invention concerns compositions comprising and methods of identification and use of targeting peptides for placenta or adipose tissue. In certain embodiments, the targeting peptides comprise part or all of SEQ ID NO:5-11, SEQ ID NO:13-22 or SEQ ID NO:144. The peptides may be attached to various therapeutic agents for targeted delivery. Adipose-targeting peptides may be used in methods for weight control, inducing weight loss and treating lipodystrophy syndrome. Adipose-targeting may also be accomplished using other binding moieties selectively targeted to adipose receptors, such as a prohibitin receptor protein complex. Placenta-targeting peptides may be used to interfere with pregnancy, induce labor and/or for targeted delivery of therapeutic agents to placenta and/or fetus. In other embodiments, receptors identified by binding to placenta-targeting peptides may be used to screen compounds for potential teratogenicity. An exemplary placental receptor is FcRn/β 2 M, and compounds that bind to FcRn/β 2 M are potential teratogens.
BACKGROUND: Anti-amyloid-β (Aβ) immunotherapy trials have revealed amyloid-related imaging abnormalities (ARIA) as the most prevalent and serious adverse events linked to pathological changes in cerebral vasculature. Recent studies underscore the critical involvement of perivascular macrophages and the infiltration of peripheral immune cells in regulating cerebrovascular damage. Specifically, Aβ antibodies engaged at cerebral amyloid angiopathy (CAA) deposits trigger perivascular macrophage activation and the upregulation of genes associated with vascular permeability. Nevertheless, further research is needed to understand the immediate downstream consequences of macrophage activation, potentially exacerbating CAA-related vascular permeability and microhemorrhages linked to Aβ immunotherapy.
METHODS: This study investigates immune responses induced by amyloid-targeting antibodies and CAA-induced microhemorrhages using RNA in situ hybridization, histology and digital spatial profiling in an Alzheimer's disease (AD) mouse model of microhemorrhage.
RESULTS: In the present study, we have demonstrated that bapineuzumab murine surrogate (3D6) induces profound vascular damage, leading to smooth muscle cell loss and blood-brain barrier (BBB) breakdown. In addition, digital spatial profiling (DSP) reveals that distinct immune responses contribute to vascular damage with peripheral immune responses and perivascular macrophage activation linked to smooth muscle cell loss and vascular fibrosis, respectively. Finally, RNA in situ hybridization identifies two distinct subsets of Trem2+ macrophages representing tissue-resident and monocyte-derived macrophages around vascular amyloid deposits. Overall, these findings highlight multifaceted roles of immune activation and vascular damage in driving the development of microhemorrhage.
CONCLUSIONS: In summary, our study has established a significant link between CAA-Aβ antibody immune complex formation, immune activation and vascular damage leading to smooth muscle cell loss. However, the full implications of this cascade on the development of microhemorrhages requires further exploration. Additional investigations are warranted to unravel the precise molecular mechanisms leading to microhemorrhage, the interplay of diverse immune populations and the functional roles played by various Trem2+ macrophage populations in response to Aβ immunotherapy.
MET in additional to conventional treatment. MET was applied to Upper trapezius, Levator scapulae and Scalene Following the 7-10 seconds isometric contraction and complete relaxation of all elements, the stretch is maintained for 30 seconds. The effort and the counter-pressure should be modest (20% of available strength) and painless. The process is repeated 3-5 times.
Process for prepn. of pure, crystalline anthocyanosides, in the form of perfectly defined chemical species, starting from plant material contg. the anthocyanosides, by extn. with an alcoholic acid solvent, opt. after a preliminary washing of the starting material with an acidified ketone (e.g. acetone) to remove various impurities, is characterised in that after extn. of the anthocyanosides by means of the alcoholic acid solvent (e.g. acidified methanol) and evapn. of the extract to dryness, the residue is suspended in a solvent (e.g. n-butanol) which forms an azeotrope with water and azeotropically distilled to dehydrate the extract. The dried extract is dissolved in an alcoholic acid solvent (e.g. acidified methanol) and the anthocyanosides precipitated by addition of a ketone (e.g. acetone). The anthocyanosides are then crystallised from aqueous acid medium. Anthocyanosides have almost no toxicity and are strong dyes useful in the food, cosmetic and dermo-pharmaceutical industries. They are rapidly absorbed and increase capillary resistance, reduce capillary permeability and are used in ophthalmology, to give vascular protection and also have antiinflammatory radiation protecting, flood platelet aggregation inhibiting, antiviral, antineoplastic, enzyme inhibitory, and collagen biosynthesis affecting activity. Pharmacological and clinical tests are described.
The intravenous infusion of nesiritide consisted of a bolus dose of 2mcg/kg followed by the infusion rate of 0.01 mcg/kg/min for up to eight hours. The nesiritide was mixed in 250 ml of 0.9% normal saline solution.
Minimal residual disease (MRD) based risk stratification criteria for specific genetic subtypes remained unclear in childhood acute lymphoblastic leukemia (ALL). Among 723 children with newly diagnosed ALL treated with the Chinese Children Leukemia Group CCLG-2008 protocol, MRD was assessed at time point 1 (TP1, at the end of induction) and TP2 (before consolidation treatment) and the MRD levels significantly differed in patients with different fusion genes or immunophenotypes (P all < 0.001). Moreover, the prognostic impact of MRD varied by distinct molecular subtypes. We stratified patients in each molecular subtype into two MRD groups based on the results. For patients carrying BCR::ABL1 or KMT2A rearrangements, we classified patients with MRD < 10-2 at both TP1 and TP2 as the low MRD group and the others as the high MRD group. ETV6::RUNX1+ patients with TP1 MRD < 10-3 and TP2 MRD-negative were classified as the low MRD group and the others as the high MRD group. For T-ALL, We defined children with TP1 MRD ≥ 10-3 as the high MRD group and the others as the low MRD group. The 10-year relapse-free survival of low MRD group was significantly better than that of high MRD group. We verified the prognostic impact of the subtype-specific MRD-based stratification in patients treated with the BCH-ALL2003 protocol. In conclusion, the subtype-specific MRD risk stratification may contribute to the precise treatment of childhood ALL.
Twenty soccer players will be randomized (1:1 ratio) into intervention and control groups. The study will last 4 weeks, divided into two periods: baseline (2 weeks) and intervention (2 weeks). In the baseline period, the players will maintain their normal routine and their sleep habits will be monitored by actigraphy and sleep diaries. The players physical performance will be assessed by the 30-15 intermittent fitness test, countermovement jump, isometric mid-thigh pull and 30-meter sprint, while the cognitive performance will be assessed with the 3-minute psychomotor vigilance test. During the intervention period, the intervention group will extend their usual time in bed by 25% than their baseline period, and adopt sleep hygiene behaviors, while the control group will maintain their usual sleep routine. The physical performance of the players of both groups will be assessed with the same physical tests of the baseline period at the end of week 1 and week 2.
The diagnosis of an enteropathic disease or the response of a patient with an enteropathic disease to therapy, in a clinical trial setting or in a long-term disease management setting, is assessed by detecting the ability of the patient to metabolize an orally administered gluten peptide analog. The peptide metabolism may be monitored in a variety of ways. Conveniently, the appearance of a metabolite of the peptide is detected in a patient sample over a period of time following oral administration, e.g. in urine, plasma, breath, saliva, etc. The gluten peptide analog is optionally labeled, e.g. with an isotopic, fluorescent, etc. label.